Adaptimmune

Adaptimmune is strengthening its Board

paul.newey — Mon, 19 Sep 2011 08:00:56 +0000

Adaptimmune announces New Board Appointments as clinical programmes get underway. Please click here for Press Release

Opening of Pilot Clinical Trial in Synovial Sarcoma

paul.newey — Mon, 25 Jul 2011 08:00:45 +0000

Adaptimmune announced today that it has opened a Pilot, open‐label clinical trial in synovial sarcoma at the National Cancer Institute (NCI), Bethesda, Maryland. Please click here for Press Release

Opening of Phase I/II Clinical Trial for Metastatic Melanoma

paul.newey — Mon, 13 Jun 2011 11:23:35 +0000

Adaptimmune announced today that it has opened a Phase I/II, two cohort, open label clinical trial in metastatic melanoma at Washington University, St. Louis, Missouri. Please click here for Press Release

Opening of Phase I/II Clinical Trial in Multiple Myeloma

paul.newey — Thu, 26 May 2011 10:04:31 +0000

Adaptimmune has opened a Phase I/II, dual site, two-cohort, open-label clinical trial in multiple myeloma at the University of Maryland and the University of Pennsylvania testing its enhanced T cell receptor T cell therapy. Please click here for Press Release

Adaptimmune announces launch of US Subsidiary

paul.newey — Mon, 07 Mar 2011 14:21:11 +0000

Adaptimmune Limited today announced that it has launched a US subsidiary, Adaptimmune LLC, located in Philadelphia, and appointed Dr Gwen Binder-Scholl as Vice President of Operations of the new company.

Please click on this link to download the full Press Release

Adaptimmune announces first ever clinical trial with engineered T cells designed to clear HIV infection

paul.newey — Wed, 07 Oct 2009 13:04:53 +0000

Researchers at Adaptimmune and the University of Pennsylvania announce the approval of an IND and opening for enrolment of the first ever study using engineered T cells to treat HIV

Adaptimmune announces first ever clinical trial with engineered T cells designed to clear HIV infection

paul.newey — Wed, 07 Oct 2009 12:56:40 +0000

October 7th, 2009

Oxford, UK and Philadelphia, PA: 7 October 2009. Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine announce the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrolment of the first ever study using patients’ cells carrying an engineered T cell receptor to treat HIV. The trial may have important implications in the development of new treatments for HIV potentially slowing – or even preventing – the onset of AIDS.

See press release below:-

Adaptimmune Ltd Press Release – 07 Oct 2009

——————————————————————————————

The T Cell Processing Laboratory for the Generation of Engineered T cells Designed to Fight HIV Infection – Cell sorting.

Cell sorting – Patient cells are separated out to focus on the population best suited for targeting the HIV-infected cells. They are then carefully expanded and prepared using the modified T cell receptor.

——————————————————————————————

The T Cell Processing Laboratory for the Generation of Engineered T cells Designed to Fight HIV Infection – Final harvesting.

Final harvesting – after a period in culture, the patient’s cells are harvested, extensively tested and then re-administered to the patient.

Press Release: Adaptimmune engineers immune cells able to clear HIV – clinical trials planned

paul.newey — Mon, 10 Nov 2008 08:23:07 +0000

Click below to download Press Release :-

Adaptimmune Ltd Press Release – 09 Nov 2008

Adaptimmune officially founded

paul.newey — Fri, 25 Jul 2008 09:46:31 +0000

Adaptimmune was officially founded on the 1st July 2008 with the remit of advancing the use of engineered T cell receptors in adoptive T cell therapy.